March 29 (Reuters) - Rocket Pharmaceuticals Inc :
* ROCKET PHARMACEUTICALS RECEIVES EMA PRIORITY MEDICINES (PRIME) DESIGNATION FOR RP-L201 GENE THERAPY FOR TREATMENT OF LEUKOCYTE ADHESION DEFICIENCY-I
* ROCKET PHARMACEUTICALS - LOOK FORWARD TO SHARING INITIAL PHASE 2 DATA FROM POTENTIALLY REGISTRATION-ENABLING LAD-I TRIAL IN Q2 OF 2021
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
* ROCKET PHARMACEUTICALS RECEIVES EMA PRIORITY MEDICINES (PRIME) DESIGNATION FOR RP-L201 GENE THERAPY FOR TREATMENT OF LEUKOCYTE ADHESION DEFICIENCY-I
* ROCKET PHARMACEUTICALS - LOOK FORWARD TO SHARING INITIAL PHASE 2 DATA FROM POTENTIALLY REGISTRATION-ENABLING LAD-I TRIAL IN Q2 OF 2021
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)